Literature DB >> 14599646

Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.

Mark J Koury, John H Newman, John J Murray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14599646     DOI： 10.1016/s0002-9343(03)00475-3

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  7 in total

1.  Leukotriene Inhibitors in Sinusitis.

Authors:  John W Steinke; Joshua L Kennedy
Journal:  Curr Infect Dis Rep       Date:  2012-01-29       Impact factor: 3.725

Review 2.  Primary eosinophilic disorders: a concise review.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 3.  Mepolizumab in eosinophilic disorders.

Authors:  J Pablo Abonia; Philip E Putnam
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

Review 4.  Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Authors:  Ayalew Tefferi; Jason Gotlib; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2010-01-06       Impact factor: 7.616

Review 5.  Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Authors:  Ayalew Tefferi; Animesh Pardanani
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

Review 6.  Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.

Authors:  Florence Roufosse
Journal:  Front Med (Lausanne)       Date:  2018-04-06

7.  A Case of Chronic Eosinophilic Leukemia in a Patient With Recurrent Cough, Dyspnea, and Eosinophilia.

Authors:  Nino Balanchivadze; James P Purtell; Jessica Anderson; Yue Guo; Irina Dobrosotskaya
Journal:  Cureus       Date:  2021-01-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.